Immediate Impact

2 by Nobel laureates 71 standout
Sub-graph 1 of 20

Citing Papers

Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2024 Standout
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
17 intermediate papers

Works of Romil Chadha being referenced

The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)
2007
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
2007
and 1 more

Author Peers

Author Last Decade Papers Cites
Romil Chadha 71 151 101 386 228 15 620
Raxitkumar Jinjuvadia 71 80 105 210 149 24 579
Touraj Mansourbakht 110 260 90 221 117 14 615
Xiaoping Wu 219 90 79 327 179 28 691
Takeo Kimoto 300 128 112 424 79 27 712
Yu Wen 111 155 106 161 40 17 564
Hong Zhu 84 291 148 321 125 27 620
Kian Fong Foo 189 311 232 127 75 24 694
Donald Poon 103 222 130 242 171 19 681
Yasuhide Motoyoshi 49 134 36 303 49 27 607
Penglei Ge 91 203 187 162 73 17 574

All Works

Loading papers...

Rankless by CCL
2026